Jude Medical. In this issue of the Journal, Knops et al. (7) provide intriguing data on the mid-term results of a leadless pacemaker. This device was designed to address the complications associated with implantable pacemakers. Approximately 8% of pacemaker implants are associated with acute complications.
There are w65,000 lead failures annually in the more than 4 million implanted systems worldwide (8) . Accordingly, this is a major problem that has Based on these data, the projected longevity of this device is w10 years, even with 100% pacing. As with the other novel CIEDs, there are limitations associated with the first-generation devices.
For the leadless pacemaker, the most obvious is the ability to provide only right ventricular pacing.
Neither dual-chamber nor left ventricular pacing, to allow for cardiac resynchronization therapy, is available. Remote monitoring is not available, and the usefulness of the temperature-based rate sensor has not been established. Undoubtedly, these issues will be addressed in future generations of leadless pacemakers.
Predicting the role of this device in pacemaker therapy is a challenge, as it is for most new devices.
In the United States and most European countries, w20% to 30% of patients receive ventricular pacemakers primarily for chronic atrial fibrillation, goldmr@musc.edu.
